On Thursday, April 7, The Washington Post published a thorough, person-centric, and well-written article by reporter Laurie McGinley that we
Date: 3/24/2022
LuMind IDSC President and CEO Hampus Hillerstrom contributed to UsAgainstAlzheimer’s and the Global Alzheimer’s Platform Foundation’s recent statement in opposition to the proposed rule by the Centers for Medicare and Medicaid Services (CMS) that would deny millions of patients–including people with Down syndrome–access to life-saving Alzheimer’s treatments and clinical trials.
Date: 3/24/2022
LuMind IDSC President and CEO Hampus Hillerstrom contributed to UsAgainstAlzheimer’s and the Global Alzheimer’s Platform Foundation’s recent statement in opposition to the proposed rule by the Centers for Medicare and Medicaid Services (CMS) that would deny millions of patients–including people with Down syndrome–access to life-saving Alzheimer’s treatments and clinical trials.
March 15, 2022 Every March, the Down syndrome community honors World Down Syndrome Awareness Day on March 21 (3/21). As part of LuMind IDSC’s
EXAMINING ADULTS WITH NEUROATYPICAL CONDITIONS FOR MCI/DEMENTIA DURING COGNITIVE IMPAIRMENT ASSESSMENTS: REPORT OF THE NEUROATYPICAL CONDITIONS EXPERT CONSULTATIVE PANEL July,
Date: 2/7/2022
People with Down syndrome are far more likely than the general population to have an Alzheimer’s diagnosis by age 65, so access to a new class of Alzheimer’s drugs could not only help those with a current diagnosis but would also generate new data on the efficacy of this type of drug in people with Down syndrome. The CMS decision, if enacted, will place insurmountable roadblocks on the path to future treatment possibilities for anyone with a Down syndrome diagnosis.
This decision, if enacted, openly discriminates against people with Down syndrome, a group of people who have not been included in any of the previous or current clinical trials on Aduhelm or the other monoclonal anti-amyloid antibodies.
Read more about LuMind IDSC’s official statement on the CMS decision.
Date: 2/7/2022
People with Down syndrome are far more likely than the general population to have an Alzheimer’s diagnosis by age 65, so access to a new class of Alzheimer’s drugs could not only help those with a current diagnosis but would also generate new data on the efficacy of this type of drug in people with Down syndrome. The CMS decision, if enacted, will place insurmountable roadblocks on the path to future treatment possibilities for anyone with a Down syndrome diagnosis.
This decision, if enacted, openly discriminates against people with Down syndrome, a group of people who have not been included in any of the previous or current clinical trials on Aduhelm or the other monoclonal anti-amyloid antibodies.
Read more about LuMind IDSC’s official statement on the CMS decision.
ACTION NEEDED BY FEBRUARY 9, 2022: SUBMIT COMMENTS TO CMS SO PEOPLE WITH DOWN SYNDROME WILL HAVE EQUAL ACCESS TO
Date: 2/4/2022
Down Syndrome Affiliates in Action (DSAIA), Down Syndrome Medical Interest Group-USA (DSMIG-USA), GiGi’s Playhouse Down Syndrome Achievement Centers, Global Down Syndrome Foundation (Global), LuMind IDSC Foundation (LuMind IDSC), National Down Syndrome Congress (NDSC), National Down Syndrome Society (NDSS), and National Task Group on Intellectual Disabilities and Dementia Practices (NTG) have launched a coordinated effort to catalyze a community-wide response to the recent Centers for Medicare & Medicaid Services (CMS) proposal concerning coverage for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease.
Date: 2/4/2022
Down Syndrome Affiliates in Action (DSAIA), Down Syndrome Medical Interest Group-USA (DSMIG-USA), GiGi’s Playhouse Down Syndrome Achievement Centers, Global Down Syndrome Foundation (Global), LuMind IDSC Foundation (LuMind IDSC), National Down Syndrome Congress (NDSC), National Down Syndrome Society (NDSS), and National Task Group on Intellectual Disabilities and Dementia Practices (NTG) have launched a coordinated effort to catalyze a community-wide response to the recent Centers for Medicare & Medicaid Services (CMS) proposal concerning coverage for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease.
